Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

BACKGROUND: In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing–remitting MS. Here, we assess efficacy and safety of alemtuzumab over 12 years in CAMMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578137/
https://www.ncbi.nlm.nih.gov/pubmed/32583052
http://dx.doi.org/10.1007/s00415-020-09983-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578137/
https://www.ncbi.nlm.nih.gov/pubmed/32583052
http://dx.doi.org/10.1007/s00415-020-09983-1

Ejemplares similares